ERA-NET PathoGenoMics M. Karrasch, FZJ 13.01.2005 WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape PathoGenoMics ERA-NET

ERA-NET PathoGenoMics

M. Karrasch, FZJ13.01.2005

WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape

PathoGenoMicsERA-NET

WP 2 Policy maker workshop of common understanding:

Survey on the national programmes

7th April 2005, Bonn




9/04 9/06 9/099/089/05 9/07

WP 3 FR Strategic and analytic activities

WP 4 FR Economic exploitation and job creation

WP 5 FI Support for transnational consortium building

WP 6 AT Human resources development and mobility

WP 7 HU Management concept and tools

WP 9 IL Science and society issues

WP 8 SP Implementing transnational activities

Contracts 1st roundContracts 2nd round

Month 0 24 604812 36

WP 2 DE Knowledge base for RTD strategies

WP 1 DE Status-quo of partner programmes

WP 10 DE Consortium management




Deliverable No.: D 1.2 Information documents on the national programmes

Delivery date: due Month 5 (in January 2005)Nature: ReportDissemination level: PP

Aim: Basis for development of best practices in programme implementation and management




Questionnaire: Survey on the national RTD programmes

Part A: General Programme Description:A1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statistics

Part B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of

programme and projects

Questionnaire: Survey on the national RTD landscape

Details on the national / regional Pathogenomics RTD landscapeResearch Content, Expertise Mapping, Economic Stakeholders




A: General Programme Description

Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of






Preceding Programmes:no

Programme Name: GEN-AU – Austrian Genome Research Programme

Programme Owner: BMBWK – Federal Ministry of Education, Science and Culture

Programme Management Agency: Programme Office GEN-AU

Part of the larger Programme: no

Topic: genome research

Objective: e.g. enhance national competitiveness, strengthen research capacities, inprove conditions for investments

Start Year: 2001

End year: 2010

Further information: www.genomik.gen-au.at

Funding by:BMBWK 100%

Total No. of funded projects: 2 No. of running projects: 2

Funded by the Programme:- 2 Universities

- 1 public Research Institute

Total funding volume per year:10.0 mio € (2004)

(0.47 mio € Pathog.)Fixed Bugdet:

yes

A: General Programme Description AT

Next update / redesign: in process




Programme Name: MICMAN – Microbes and Man

Programme Owner: Academy of Finland and The Swedish Foundation for Strategic Research

Programme Management Agency: National Public Health Institute


Topic: research on human-relevant microorganisms

Objective: increase the knowledge of the interaction between host and microbe and apply this knowledge

Start Year: 2003

End year: 2005

Further information: www.aka.fi/micman

Funding by:Research Academy 76%Private foundation 24%

Next update / redesign: none

Total No. of funded projects: 15No. of running projects: 15 ( 7 cons. of 2-4 Res. groups)


- 2 public Research Institutes- 1 Regulatory Body


Total funding volume per year:

1.8 mio €

Fixed Bugdet:yes

A: General Programme Description FI




Programme Name:

Programme Owner:

Programme Management Agency:

Part of the larger Programme

Topic:

Objective:

Start Year:

End year:

Further information:

Funding by:- -

Total No. of funded projects: List of running projects:

Funded by the Programme:- - -

Preceeding Programmes:- -

A: General Programme Description FR

Next update / redesign:

8FixedBudget: yes/no

No data submitted





Programme Name: Competence Center PathoGenoMik

Programme Owner: BMBF – Federal Ministry of Education and Science

Programme Management Agency: PTJ

Part of the larger Programme: GenoMik (Genome Research in microorganisms)

Topic: genome research on bacteria (GenoMik)

Objective: use of the potential of microbial genomes for e.g. defeating human diseases

Start Year: 2001

End year: 2006

Further information: www.genomik.uni-wuerzburg.de

Funding by:BMBF (88.9%)

involved companies (11.1%)



- 2 Medical Centres- 4 public Research Institutes

- 6 Companies


3.63 mio € (BMBF)(2003)

Fixed Bugdet:yes

A: General Programme Description DE





Programme Name:

Programme Owner:


Part of the larger Programme:

Topic:

Objective:

Start Year:

nd year:


Funding by:

Total No. of funded projects: No. of running projects:

Funded by the Programme:

Preceding Programmes:


Fixed Bugdet:

A: General Programme Description HU


No data submitted




Programme Name: NA

Programme Owner: CSO-MOH – The Chief Scientist Office, Ministry of Health

Programme Management Agency: NA


Topic:

Objective:

Start Year: continous

End year: continuos

Further information: www.health.gov.il

Funding by:CSO-MOH 100%


Funded by the Programme:- Universities

- Medical Centres- public Research Institutes



Fixed Bugdet:no

A: General Programme Description IL





Programme Name: Molecular and epidemiological study of multiresistence and genetic variability of infections

Programme Owner: Latvian Council of Science


Part of the larger Programme NA

Topic:

Objective:

Start Year: 1998

End year: 2005

Further information: www.lzp.lv

Funding by:- LCS


Funded by the Programme:- 100% Universities

Preceeding Programmes:- funct. Stability of microb. cultures-Genotoxicity by microorganisms-Mol. Studies on Borrellia burgd.


0,08 mio €

A: General Programme Description LV

Next update / redesign: 2005

Fixed Budget:yes




Programme Name:

Programme Owner:


Part of the larger Programme

Topic:

Objective:

Start Year:

End year:


Funding by:- -

Total No. of funded projects: List of running projects:

Funded by the Programme:- - -

Preceeding Programmes:- -


..mio €

A: General Programme Description PT


FixedBudget: yes/no

No data submitted




Programme Name: (10 different programmes)

Programme Owner: Ministry of Higher Education, Science and Technology

Programme Management Agency: programme managers in diverse institutions/Universities

Part of the larger Programme: national programme for financing research programmes

Topic: 1. target research programme 2. mol. Biology of microorganisms; pharmacolog. Chemistry; nutrition and ecology of gastroint. Tract; toxins and biomembranes etc.

Start Year: 2001 / 2004

End year: 2006 / 2008

Further information: website in slovenian language

Funding by:- 100% MESC- 47% MESC

- 47% Min. of Agric. For. + Food- 6% Min. of Health

Total No. of funded projects: 800 List of running projects: 450


- 4 Medical Centers-39 Public Res. Inst.

-1 priv. res. Inst.-1 company

Preceeding Programmes:- No / yes

Total funding volume per year:0,496 mio € 2004(6th them. Prior.)

A: General Programme Description SV

Next update / redesign: 2006 / 2008

FixedBudget: no




Programme Name: 1. Strategic Action on Genomics and Proteomics

2. Biotechnology

Programme Owner: Ministry of Education and Science


Part of the larger Programme: National Plan of R&D

Topic: different topics (e.g. genomics, proteomics etc.)

Objective: functional analysis of genomes of human pathogens, characterisation of novel targets, pathogenicity mechanisms, host-pathogen-interactions, development of diagnostic tools

Start Year: 2004

End year: 2007

Further information: web site in national language

Funding by:MEC 100%



- 4 Medical Centres- 10 public Research Institutes

Preceding Programmes:Yes

National R&D plan 2000-03


Fixed Bugdet:no

A: General Programme Description ES

Next update / redesign: 2007




Next Programme update / redesign

Partner Update / redesign date

Austria In process

Finland No re-design

France

Germany Programme ends 2006; no update, but new programme

Hungary

Israel Continous programme

Latvia 2005

Portugal

Slovenia 2006

Spain 2007




who is funded by the programme?

0

10

20

30

40

50

60

Austria Finland Germany Israel Latvia Slovenia Slovenia Spain Spain

funded institutions

tota

l n

um

ber

of

fun

ded

in

stit

uti

on

s

other

companies

regulatory bodies

private research institutes

public research institutes

Medical Centers

Universities

funded Institutions




Project Analysis (projects related to PatoGenoMics)

Austria 2 150 - 320 240 27

Partner Total no. of projects Range of annual budgets (1000 €)

Average annual project budget (1000 €)

Average duration of a project (months)

Finland 15 (7 consortia of

2-4 groups)

17 - 117 63 36

France

Germany 47 (9 project groups of 1-7 groups)

31 - 389 80 57

Hungary

Israel 14 15 - 29 15 12

Latvia 9 2 – 10 8 96

Portugal

Slovenia NA / 67 – 403 6 / 135 36 / 60

Spain 56 12 – 165 / 6 - 130 59 / 44 36 / 36










Programme Design Process

Partner Top-down (idea was born and implemented by the funding authority)

Bottom-up (idea was born by others e.g. beneficiaries of funding)

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain




Programme / CallContents / text

First idea

MinistriesAT – BMBWKDE – BMBF

Scientific communities:AT, FI, IL, LV, SL, ES

Research councils AT, LV, SL

Editing of the Call text

Analysis Initiation phase:Who influencesthe programmedesign?

Boards/ institutions:• Scientific Advisory Board: AT, DE, LV• Research Councils: AT, LV, SL

Ministries/funding authorities/CommitteesAT – BMBWKFI – Steering Programme CommitteeDE – BMBFIL – CSO-MOHLV – Program leaderSL – Ministry of Science and

TechnologyES – MEC

influ

ence











Electronical Application/Submission System

Partner Electr. System used

No electr. system

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain




Rules for Submission System obligatory optional

Austria Not available Paper Version

Finland Signature only Electr. System

France

Germany both

Hungary

Israel

Latvia

Portugal

Slovenia Not available Paper Version

Spain Electr. System

Partner Electr. System Paper Version Most common subm. way




Application Support

Partner Written Manual Electronic guidance

Helpdesk / contact person

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain




Application Process: 1 step or 2 step approach

Partner 1 step-approach (full proposals) 2 step-approach (draft and full proposal

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain




Steps during Application• (draft proposal submission)• (draft proposal evaluation): AT, FI

Structure of draft: - Short description

of the project- Organisational and

scientific concept

Summary: Application / Submission Procedure

Support of applicants by:- Written manual: all except LV

- Electr. Guidance: all- Helpdesk/contact person: all

Approach: 2-stepDrafts + full proposals: AT, FI

Submission:-Electronically: FI, DE, IL, LV, ES

-paper: AT, FI, DE, IL, LV, SL

Elements of full proposals: - Name, coordinates, CV researcher(s)- scientific/technical description- Cost and time schedule- Management/organisation of networks- HR/ethical aspects- Relevance to programme- Relevance to industrial application

Approach: 1-stepfull proposals: DE, IL, LV, SL, ES

Rules of procedure by:- ministry: AT, DE, IL, SL, ES

- Academy/Council: FI, LV

• full proposal submission• full proposal evaluation: DE, IL, LV, SL, ES




Is the call permanently open or are there cut-off dates?

Partner Permanently open (no direct competition of proposals)

Cut-off dates (direct competition of proposals)

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain





Part A: General Programme DescriptionA1: General Programme InformationA2: History and Road Map of the ProgrammeA3: Programme / Project statisticsPart B: Programme management and implementation approachesB1: Programme InitiationB2: Application / Submission ProcedureB3: Evaluation ProcessB4: Financial modalities, Legal and Contractual FrameworkB5: Project management, administrative procedures and Review of programme and projects





Partner Funding authority

External advisory board

Peer review Hearing of applicant

Presentation by applicant

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain

Evaluation Process - Evaluation by:




Evaluation Process: Stakeholders present among the evaluators

Partner Ministry

Manage-ment Agency

Research Council

Industry Organi-sation

Compa-ny

Single Scientist

Scientific Socie-ties

Experts from abroad

other

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain




Evaluator characteristics

Evaluators

• Evaluation by funding agency/authority: AT, FI, IL, LV, SL, ES• Evaluation by external advisory board: AT, FI, DE, SL, ES• Evaluation by peer review: AT, IL, SL

From Industry:AT, (IL), LV, ES

From abroad:AT, FI, DE, LV, ES

Standing board:DE, LV, SL




Are the Evaluators known to the Applicants?

Partner yes no

Austria

Finland After the funding decision

France

Germany Some are known

Hungary

Israel Known post evaluation

Latvia

Portugal

Slovenia

Spain




Can the final Evaluation result be overruled?

Partner yes no

Austria final decision is subject to the ministry

Finland final ranking by the programme Steering committee

France

Germany Evaluation may be overruled by the project management agency and the ministry

Hungary

Israel

Latvia Written complaint to Latvian Council of Science

Portugal

Slovenia Final decision by the funding bodies

Spain




Evaluation criteria

5

2

5

7

21

13

3

13

7

5

15

7

14

19

910

4

0

5

10

15

20

25

Eth

ical

issu

es

Gen

der

issu

es

Inte

rnat

iona

l

com

petit

iven

ess

Inte

rnat

iona

lity

Inno

vativ

e

pote

ntia

l, no

velty

,

scie

ntifi

c re

cord

of a

pplic

ant

/ te

am

Mul

tidis

cipl

inar

itiy

pote

ntia

l of

appl

ican

t /

team

Pro

ject

/res

ourc

e

man

agem

ent

stan

dard

of

writ

ten

prop

osal

Rel

evan

ce t

o

indu

stria

l

Rel

evan

ce t

o

infr

astr

uctu

re

Rel

evan

ce t

o th

e

prog

ram

me

Sci

entif

ic q

ualit

y

of p

ropo

sal

Soc

ieta

l val

ue

Tra

inin

g as

pect

s

Tra

nsfe

r of

expe

rtis

e, m

obili

ty

sco

re

Analysis: Evaluation Criteria




imp. eval. criteria per country

0

5

10

15

20

25

most important evaluation criteria

sc

ore

Spain

Slovenia 2

Slovenia

Latvia

Israel

Germany

Finland

Austria

Analysis: most important Evaluation Criteria




Analysis: most important evaluation criteria

Ranking Evaluation criteria Score points

1 Innovative potential, novelty, originality 21

2 Scientific quality of proposal 19

3 Relevance to industrial application and commercialisation

15

4 Relevance to the programme 14

5 potential of applicant / team 13

5 scientific record of applicant / team 13




Partner Change of application/

evaluation procedure

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain

Is it possible to change the rules of the application/evaluation procedure? possible impossible




0

2

4

6

8

10

12

14

Austri

a

Finlan

d

Germ

any

Israe

l

Latv

ia

Sloven

ia

Sloven

iaSpa

in

Partner

months

Time from funding notification offunding authority/agency till projectstart

Time from full proposal evaluation tillfunding notification of fundingauthority/agency

Time from full proposal submissiontill full proposal evaluation

Time from draft proposal evaluationtill full proposal submission

Time from draft proposal submissiontill draft proposal evaluation

Time from call publication to draft (full) proposal submission

How long does it take from publication of a call till start of a project?




40%from drafts

16%from drafts

23%

40%

16%

63%

0

10%

20%

30%

40%

50%

60%

70%

Austria Finland Germany Israel Latvia Slovenia Slovenia Spain Spain

project statistics: Average success rate of applications (drafts / full proposal versus funded projects)











Analysis: Funding possible impossible

Partner Synchronous calls with national funding

Joint calls with transnational funding

Austria

Finland

France

Germany

Hungary

Israel

Latvia

Portugal

Slovenia

Spain




Analysis: cost models employed

Country AT FI FR DE HU IL LV PT SV ES

FCfull cost with actual indirect costs

FCFfull cost with indirect flat rate costs

ACadditional costs with indirect flat rate costs

other











Country AT FI FR DE HU IL LV PT SV ES

Scientific/Technical Monitoring

Written reports 1/year 1/year 1/year 1/year 1/year 1/year 1/year

Oral reports/ interviews

1/year

Site visit

Seminar/conference 1/year 1/year 1/proj.

Administrative/financial Monitoring

Written reports 1/year 1-4/

year

6/year 2/year 1/year 1/year 1/year

Oral reports/ interviews

Site visit occasionally

Seminar/conference

Monitoring of ongoing projects











Relative economic Importance of Antiinfektives (2003)

Partner Percentage of health expenses to GDP (%):

percentage of pharmaceuticals to total health expenses (%):

Total pharmaceutical retail market (maker’s price) (mio €):

Anti-Infectives pharmaceutical retail market

(mio €)

Austria

Finland

France

Germany 10,8 15,9 18.900 1.400 (7,4%)

Hungary

Israel 8,8 17,1 (1997)Latvia

Portugal

Slovenia 6,2 15,9 362 NASpain (2002) 7,6 22,0 12.976 821 (6,33%)




Rank Germany Israel Slovenia Spain

1 RATIOPHARM (114) Teva Lek, d.d. (NA) GlaxoSmithKline

2 BAYER (104) Rafa Krka, d.d., Novo Mesto (0,29)

Aventis Pasteur MSD

3 PFIZER (96) Agis Esteve

4 AVENTIS (79) Farma Bayer

5 HEXAL (64) Lilly & Dista

6 GSK (51) Almirall Prodesfarma

7 ABBOTT (42) Farmacusi

8 FRESENIUS KAB.INTR (37)

Vita Group

9 MSD (33) Bohm

10 ASTRAZENECA (32)

Most important anti-infektives selling companies(antiinfektives sales per year in mio €)










Results of the national pathogenomics RTD

landscape (expertise mapping etc.):

www.pathogenomics-era.net(internal pages)










Analysis: Type of Research

basic; 7

applied; 7

Demonstration; 1 other ; 0




Analysis: Organisms studied – Phylogetenic Tree according to 16S-rRNA

XIII Aquifex

X Green Nonsulfur Bacteria

IX Deinococcus / Thermus

VIII Spirochaetes

I Proteobacteria

VII Green Sulfur Bacteria VI Bacteroides Flavobacteria group

V Planctomyces, Pirella

IV Chlamydia

III Cyanobacteria

II Gram positive BacteriaXI Thermotoga

XII Thermo-desulfobacterium I Proteobacteria

II Gram positive Bacteria

IV Chlamydia

VIII Spirochaetes





I Proteobacteria

IV Chlamydia

VIII Spirochaetes

XIII Aquifex





III Cyanobacteria

XI Thermotoga

XII Thermo-desulfobacterium





Analysis: Organisms studied

I Proteobacteria


Gram-positive cocci: e.g. Staphylococcus, Streptococcus,Pneumococcus

Gram-positive non-sporulating rods: e.g. Listeria, Mycobacterium,

CorynebacteriumGram-positive sporulating rods: e.g. Bacillus, Clostridium

Gram-positive bacteria without cell wall: Mycoplasma

Gram-negative rods: e.g. E. coli, Salmonella, Yersinia, VibrioHaemophilus, Pasteurella, Helicobacter

Obligatory intracellular bacteria: Chlamydia

IV Chlamydia

VIII Spirochaetes Gram-negative spiral bacteria: e.g. Borellia, Treponema




Organism groups studied

Gram – rodsE. coli, Salmonella, Klebsiella, Pseudomonas, Haemophilus, Bordetella, Vibrio, Helicobacter

Gram + sporulating rodsBacillus, Clostridium

Gram + without cell wallMycoplasma

17

5

371

5

1015

33Gram + cocciStaphylococcus, Streptococcus

Gram + non-sporulating rodsListeria, Mycobacterium

Eukaryotic organismsfungi

Gram – spiral bacteriaBorrellia

obl. intracellular bacteriaChlamydia







17

5

371

5

1015










Gram-negative rods: which are the most common studied species?

E. Coli spec.

E. Coli ETEC (toxin producing)

E. Coli EHEC (enterohaemorragic)

Yersinia enteroliticaYersinia spec.

Salmonella typhi

Salmonella spec.

Shigella spec.

7

5

6

3

3

33

35Pseudomonas spec.




Austria; 1Finland; 7

Germany; 20

Israel; 8

Latvia; 4

Slovenia; 0

Slovenia; 10

Spain; 11

Spain; 11

Austria

Finland

Germany

Israel

Latvia

Slovenia

Slovenia

Spain

Spain

Gram-negative rods: which are the most committed countries?








17

5

371

5

1015










5

7

4

15

2

5

1

02

2 1

Staphylococcus spec.

Staphylococcus aureus

Staphylococcus epidermidis

Streptococcus spec.

Streptococcus pneumoniae

Streptococcus pyogenes

Pneumococcus spec.

Enterococcus spec.




Austria; 2

Finland; 5

Germany; 10

Israel; 2Latvia; 3

Slovenia; 0

Slovenia; 6

Spain; 4

Spain; 4

Austria

Finland

Germany

Israel

Latvia

Slovenia

Slovenia

Spain

Spain

Gram-positive cocci: which are the most committed countries?








17

5

371

5

1015









Gram-positive non-sporulating rods : which are the most common studied species?

5

3

4

2

1

2

1

Listeria monocytogenes Streptomyces spec.

Mycobacterium spec. Mycobacterium tuberculosis

Mycobacterium bovis




Gram-positive non-sporulating rods : which are the most committed countries?

Germany; 3

Israel; 1

Latvia; 2

Slovenia; 2Spain; 5

Spain; 5Austria

Finland

Germany

Israel

Latvia

Slovenia

Slovenia

Spain

Spain








17

5

371

5

1015









Eukaryotic Organisms: which are the most common studied ones?

Yeast 3

Aspergillus 4

Candida 2 Plasmodium 2

Leishmania 3

Echinococcus 1

other; 4 Yeast

Aspergillus

Candida

other (please specify):

- other:

Trypanosoma

Plasmodium

Leishmania

Echinococcus granulosus

other (please specify):




Eukaryotic Organisms: which are the most committed countries?

Finland; 1

Israel; 3

Slovenia; 4

Spain; 5

Spain; 5 Austria

Finland

Germany

Israel

Latvia

Slovenia

Slovenia

Spain

Spain








I Proteobacteria

XIII Aquifex



VIII Spirochaetes



IV Chlamydia

III Cyanobacteria

II Gram positive BacteriaXI Thermotoga

XII Thermo-desulfobacterium

Alpha: e.g. Acetobacter, Agrobacterium, Gluconobacter, Paracoccus, Rhodospirillum,Rhizobium, Zymomonas

Beta: e.g. Neisseria, Pseudomonas (some), Spirillum

Gamma: e.g. Escherichia, Legionella, Salmonella and other intestine bacteria, Vibrio

Delta: e.g. sulfate reducing bacteria, Myxobacteria, Xanthomonas (some)

Epsilon: e.g. Campylobacter, Helicobacter, Xanthomonas (some)






XIII Aquifex



VIII Spirochaetes

I Proteobacteria



IV Chlamydia

III Cyanobacteria

XI Thermotoga

XII Thermo-desulfobacterium I Proteobacteria

Non sporulating gram+ bacteria, low G+C content:e.g. Staphylococcus, Streptococcus, Micrococcus, Lactobacillus, Enterococcus, Listeria

Endosporulating gram+ bacteria, low G+C content: e.g. Bacillus, Clostridium

Bacteria without cell wall: Mycoplasma

gram+ bacteria, high G+C content:e.g. Corynebacterium, Mycobacterium, Actinomycetes

Documents

ERA-NET PathoGenoMics M. Karrasch, FZJ 13.01.2005 WP 1 Status-quo of partner programmes T 1.1 Survey national programmes/RTD landscape PathoGenoMics ERA-NET